Stratosvir
Stratosvir is a UK-based pre-clinical biotechnology company developing third-generation engineered oncolytic viral immunotherapies with systemic intravenous delivery capability for advanced solid tumours, with a focus on prostate cancer.
- Company typePrivate
- Founded2020
- HeadquartersIngatestone, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Stratosvir does
Stratosvir is a UK-based, pre-clinical biotechnology company developing engineered oncolytic viral immunotherapies for advanced solid tumours, with a particular emphasis on prostate cancer. The company was originated as a spin-out from Cancer Research Horizons and Deep Science Ventures and operates from the Stevenage Bioscience Catalyst, a recognised UK cell-and-gene therapy cluster. The intended end users of the eventual therapy are oncology patients with treatment-refractory solid tumours, while the company's direct customers and revenue counterparties, once commercialisation is reached, are expected to be larger biopharmaceutical firms via out-licensing or co-development arrangements.
The core technology is a third-generation engineered oncolytic virus platform designed to overcome the principal limitation of earlier oncolytic virus generations: the inability to be administered systemically via intravenous (IV) infusion. Stratosvir's engineered viruses are intended to be delivered IV and to selectively replicate within tumour tissue, combining direct oncolysis with anti-tumour immune activation. The company is also building STARLITE, a next-generation discovery platform funded under an Innovate UK grant with a UK-Germany bilateral collaborative R&D component, intended to expand the platform's reach across additional solid tumour indications.
The current business model is research-stage and capital-consuming rather than revenue-generating. Stratosvir finances its discovery and pre-clinical work through a combination of equity investment from specialist UK biotech backers (o2h Ventures, Proven Connect), co-investment from Cancer Research Horizons, and non-dilutive grant funding from Innovate UK. With approximately five core team members and no disclosed product licensing deals, the company has no commercial revenue. The path to monetisation is expected to follow standard UK oncology biotech conventions: progress the lead candidate through pre-clinical and early clinical development, then partner or out-license to a larger pharmaceutical company for late-stage development and commercialisation.
Stratosvir firmographics
Firmographics- Name
- Stratosvir
- Legal name
- Stratosvir Ltd.
- Website
- https://stratosvir.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Stratosvir is a UK-based pre-clinical biotechnology company developing third-generation engineered oncolytic viral immunotherapies with systemic intravenous delivery capability for advanced solid tumours, with a focus on prostate cancer.
- Ownership category
- akta.pro rank
Stratosvir industry classification
Industry- Product category
- Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
Keywords
Where Stratosvir is headquartered
LocationHeadquarters
- HQ city
- Ingatestone
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Stratosvir business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Viral Immunotherapy Pipeline: Pre-revenue biotech developing a pipeline of viral immunotherapy drugs for advanced cancers (including prostate cancer). Revenue is anticipated through out-licensing, co-development partnerships with pharmaceutical companies, and eventual product commercialisation upon regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Stratosvir product offering
Product offeringCore offering
Stratosvir develops a clinical-stage viral immunotherapy platform based on 3rd generation engineered oncolytic viruses that selectively replicate in tumours, destroy malignant cells, and reprogramme the immune system to attack solid tumours and metastases. The platform is designed to enable systemic (intravenous) delivery of therapeutic viruses, overcoming the intratumoral-injection barrier limiting current oncolytic virus therapies. The company is targeting advanced solid tumours and prostate cancer where existing immunotherapy response rates are only around 5%.
Product overview
Stratosvir is developing a portfolio of viral immunotherapy products centered on its core platform technology for engineering 3rd generation viruses. The platform enables systemic (intravenous) delivery of therapeutic viruses, overcoming the traditional limitation to intratumoral injection. The products include engineered oncolytic viruses designed to selectively replicate in tumours, destroy malignant cells, and reprogram the immune system. The STARLITE platform extends these capabilities for discovery and delivery of antibody immunotherapies targeting advanced prostate cancer and other late-stage solid tumours.
Differentiator
Problem solved
Functional benefit
Products and services
- Viral Immunotherapy Platform A viral immunotherapy platform engineering 3rd generation oncolytic viruses designed to selectively replicate in tumours, destroy malignant cells, and reprogramme the immune system to respond to a broad range of solid tumours and metastases. Intended for out-licensing and co-development with pharmaceutical and biotech partners.
- 3rd Generation Engineered Oncolytic Viruses Third-generation oncolytic viruses engineered for selective replication in tumours, destruction of malignant cells, and intravenous administration to deliver immunotherapy payloads to cancer cells and metastases. Targeted at patients with advanced solid tumours and metastases.
- STARLITE Immuno-Oncology Platform A complete immuno-oncology platform for discovery and delivery of novel proprietary therapeutic payloads, enabling vectorised antibody immunotherapies for the treatment of advanced prostate cancer and other late-stage cancers. Developed under the Innovate UK STARLITE bilateral UK-Germany grant.
Quantifiable outcome
- Currently only 5% of advanced prostate cancer patients respond to existing immunotherapies; Stratosvir aims to dramatically improve this rate with its next-generation viral immunotherapy.
Companies that use Stratosvir
Customer profileSegments2 records
Ideal customer profiles2 records
Stratosvir technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Stratosvir partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Innovate UK (STARLITE Grant - German Partner)coreStratosvir was awarded the STARLITE grant from Innovate UK in a bilateral UK-Germany collaborative R&D programme, in partnership with ZIM (Zentrales Innovationsprogramm Mittelstand) and a German partner company, to develop a complete immuno-oncology platform for vectorised antibody immunotherapies for advanced prostate cancer and other late-stage cancers.
- Sussex Drug Discovery Centre, University of SussexminorStratosvir has operations at the Sussex Drug Discovery Centre, University of Sussex, UK, supporting drug discovery and development activities.
- Stevenage Bioscience CatalystminorStratosvir operates from the Stevenage Bioscience Catalyst campus in Hertfordshire, UK, a leading bioscience incubator and cluster facility providing laboratory space and ecosystem support for biotech companies.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Stratosvir competitors and assessment
Company assessmentDirect peers
- Targovax: Clinical-stage immuno-oncology company developing oncolytic virus-based therapies (ONCOS-102) targeting solid tumours. Pursues an analogous approach combining oncolytic viral therapy with immune activation.
- Oncolytics Biotech: Pioneer in oncolytic virus therapy with pelareorep (reovirus-based) across multiple solid tumour indications. Pure-play peer in oncolytic immunotherapy with similar systemic-delivery ambitions and combination-therapy positioning.
- Replimune: Clinical-stage oncolytic immunotherapy company developing its RP1/RP2/RP3 platform for solid tumours. Directly comparable in modality (engineered oncolytic virus), indication focus (solid tumour immunotherapy), and go-to-market model (partnering/asset deals with pharma).
- Turnstone Biologics: Clinical-stage biotech developing oncolytic virus immunotherapies that combine tumour lysis with immune stimulation, with similar R&D and partnership profile to Stratosvir's STARLITE-engineered approach.
- Genelux Corporation: Clinical-stage oncolytic immunotherapy company developing engineered vaccinia-based viruses (Olvimulogenic nanoplex) for solid tumours. Directly comparable in modality and approach to engineering tumour-selective viruses.
- PsiOxus Therapeutics (now Akamis Bio): Closest historical peer — oncolytic virus platform company for solid tumours, whose leadership alumni (CSO and Chairman) founded Stratosvir. Engages an identical therapeutic modality (engineered oncolytic viruses) for solid tumour immunotherapy with overlapping scientific heritage.
- CG Oncology (formerly Cold Genesys): Late-clinical-stage oncolytic virus immunotherapy company with cretostimogene in bladder cancer. Operates in the same modality and pursues similar partnering strategy, including a major deal with Pfizer.
Broad incumbents
- ImmunityBio: Late-stage immunotherapy company combining cytokines, antibodies, and oncolytic approaches (Anktiva/N-803 in bladder cancer, with checkpoint combination programmes). Operates in overlapping immunotherapy and prostate/bladder cancer spaces and competes for the same pharma BD mindshare.
- SillaJen: Established Korean clinical-stage biotech developing Pexa-Vec (pexastimogene devacirepvec) — one of the more clinically advanced oncolytic virus candidates. Directly comparable modality and oncology indications.
- Amgen (IMLYGIC/T-VEC): The only FDA-approved oncolytic virus therapy (talimogene laherparepvec/T-VEC in melanoma). Defines the commercial reference point for the entire oncolytic virus class and is a likely out-licensing acquirer for Stratosvir's platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Stratosvir social profiles
Digital presenceStratosvir financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stratosvir leadership team
Management profileNumber of profiles
Profiles5 records
Stratosvir funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stratosvir M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stratosvir
What does Stratosvir do?
Stratosvir develops a clinical-stage viral immunotherapy platform based on 3rd generation engineered oncolytic viruses that selectively replicate in tumours, destroy malignant cells, and reprogramme the immune system to attack solid tumours and metastases. The platform is designed to enable systemic (intravenous) delivery of therapeutic viruses, overcoming the intratumoral-injection barrier limiting current oncolytic virus therapies. The company is targeting advanced solid tumours and prostate cancer where existing immunotherapy response rates are only around 5%.
Is Stratosvir a public or private company?
Stratosvir is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stratosvir founded?
Stratosvir was founded in 2020. It employs 1 to 10 people.
Where is Stratosvir based?
Stratosvir is headquartered in Ingatestone, United Kingdom, in the Europe region.
How does Stratosvir make money?
One revenue line is on record: viral Immunotherapy Pipeline.
Who are Stratosvir's main competitors?
Direct peers on record are Targovax, Oncolytics Biotech, Replimune, Turnstone Biologics, Genelux Corporation, PsiOxus Therapeutics (now Akamis Bio) and CG Oncology (formerly Cold Genesys). Broad incumbents are ImmunityBio, SillaJen and Amgen (IMLYGIC/T-VEC).
Does Stratosvir have an API?
No public API is recorded for Stratosvir.
What industry is Stratosvir in?
Stratosvir's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.